AbbVie
PulseAugur coverage of AbbVie — every cluster mentioning AbbVie across labs, papers, and developer communities, ranked by signal.
2 day(s) with sentiment data
-
Reed Jobs's Yosemite raises $350M for non-lethal cancer initiatives
Reed Jobs's venture firm Yosemite has successfully raised $350 million for its second fund, significantly increasing its capital from the initial close of $200 million. The firm's mission is to invest in technologies an…
-
Biotech IPOs surge with over two dozen companies public this year
The biotech sector has seen a significant increase in companies going public this year, with over two dozen already having completed their IPOs. This trend is expected to continue, with more companies preparing to enter…
-
Galderma invests $650M in U.S. manufacturing amid European FDI surge
Galderma, a Swiss dermatology company, is significantly increasing its investment in U.S. manufacturing, planning to spend over $650 million by 2030. This move is part of a broader trend of European companies expanding …
-
Warren Buffett warns against speculative investing, highlighting biotech's gambling-like risks
Warren Buffett has cautioned against the increasing speculative nature of the stock market, drawing a parallel to the biotechnology sector. He noted that while he prefers businesses he can understand with predictable ca…
-
Eli Lilly acquires AtaiBeckley for $3.8B, signaling Big Pharma's major bet on psychedelic medicine
Eli Lilly has announced a significant acquisition of AtaiBeckley for up to $3.8 billion, marking the largest deal in the psychedelic medicine sector. This move, along with AbbVie's prior acquisition, signals a major shi…
-
Autoimmune disease therapies boom amid VC investment; OpenAI targets healthcare
The field of autoimmune disease therapies is experiencing a significant boom, with projected revenues for drugs like AbbVie's Skyrizi expected to reach $33 billion by 2032. This growth is driven by scientific breakthrou…
-
AbbVie buys Apogee for $10.9B; AI startup Cadence raises $100M
AbbVie has acquired Apogee Therapeutics for $10.9 billion to bolster its immunology franchise with Apogee's lead drug, zumilokibart, which shows promise in treating autoimmune conditions. Separately, the AI startup Cade…